From here:
Did
a developer of stem cell treatments mislead investors by boasting of
success with a patient and use the good news to sell stock while
failing to later disclose the patient died? This is the allegation
facing Pluristem Therapeutics, which insists it did not know of the
death prior to a September stock sale. A second patient died, but no
details surrounding the death are known.
Ethics? It is not relevant
in this Business. And another very important issue: so
far I cannot find any real background for accepting stem cell
treatment as a worthwhile approach. It looks like the entire stem
cell concept is used for creating a new
bubble for Big Pharma.
No comments:
Post a Comment